Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 8/20 | 0.42 |
| ▸ | PPARD | Q03181 | 5/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9555491 | 0.84 | GAA (0.49) | ALDH1A1GAANPC1MAPTKDM4E | |
| SCHEMBL27689189 | 0.81 | MAPT (0.47) | ALDH1A1GAANPC1MAPTKDM4E | |
| SCHEMBL6221150 | 0.80 | NPC1 (0.46) | ALDH1A1GAANPC1MAPTKDM4E | |
| SCHEMBL967900 | 0.78 | MAPT (0.52) | ALDH1A1GAANPC1MAPTKDM4E | |
| SCHEMBL4470686 | 0.78 | MAPT (0.56) | ALDH1A1GAANPC1MAPTKDM4E | |
| SCHEMBL4466371 | 0.77 | NPC1 (0.47) | ALDH1A1GAANPC1MAPTKDM4E | |
| SCHEMBL18003992 | 0.77 | MAPT (0.54) | ALDH1A1GAANPC1MAPTKDM4E | |
| SCHEMBL4463408 | 0.77 | NPC1 (0.47) | ALDH1A1GAANPC1MAPTKDM4E | |
| SCHEMBL4473861 | 0.77 | KDM4E (0.54) | ALDH1A1GAANPC1MAPTKDM4E | |
| SCHEMBL4473982 | 0.76 | PTPN1 (0.48) | MAPTPPARAPPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1480640-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7153878-B2 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| US-20060166983-A1 | Indole derivatives as ppar modulators | ELI LILLY AND COMPANY | 2006-07-27 | — | — | US | disclosed |
| EP-1581521-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1581491-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20050107449-A1 | Peroxisome proliferator activated receptor modulators | ELILILLY AND COMPANY | 2005-05-19 | — | — | US | disclosed |
| EP-1480640-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004092131-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004063190-A1 | FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003072100-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166983-A1 | Indole derivatives as ppar modulators | PPARA, PPARD, PPARG | ALDH1A1 1181/4885GAA 2159/4885NPC1 862/4885 |
| US-20050107449-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | ALDH1A1 1311/4885GAA 3123/4885NPC1 613/4885 |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | PPARG, PPARA, PPARD | ALDH1A1 1182/4885GAA 804/4885NPC1 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.